CEACAM6 gene expression in intrahepatic cholangiocarcinoma
CEACAM6 gene expression in intrahepatic cholangiocarcinoma
复制标题
DOI：
10.1038/sj.bjc.6603276
复制
发表时间：
2006-08-21
影响因子：
8.8
通讯作者：
Mori, M.
中科院分区：
文献类型：
--
作者：
Ieta, K.;Tanaka, F.;Mori, M.
本研究旨在探讨人癌胚抗原相关细胞粘附分子6（CEACAM6）基因在肝内胆管癌中的表达及其临床病理学意义。据报道CEACAM6参与人类恶性肿瘤。然而，CEACAM6在胆管癌中的表达及其临床病理意义尚未研究。CEACAM6的表达状态进行了测定和分析，在23个肝内胆管癌的各种临床病理参数。此外，我们还研究了CEACAM6基因在胆管癌细胞系中的作用。CEACAM6基因在23例中有16例癌组织中的表达高于非癌组织，但无统计学意义。CEACAM6表达升高的肿瘤显示出与淋巴浸润和疾病阶段相关的趋势。有趣的是，高CEACAM6表达的患者的无病生存率明显低于低CEACAM6表达的患者。我们证明，CEACAM6转染的细胞更增殖，更具侵袭性和更耐吉西他滨相比，模拟转染的细胞。此外，通过CEACAM6特异性siRNA进行的CEACAM6基因沉默导致对吉西他滨的更高化学敏感性。CEACAM6是肝内胆管癌患者吉西他滨的潜在预后指标和潜在化疗耐药标志物。
The purpose of this study was to investigate the clinicopathological and biological significance of human carcinoembryonic antigen-related cell adhesion molecule 6 ( CEACAM6) gene expression in human intrahepatic cholangiocarcinoma. CEACAM6 is reported to be involved in human malignancies. However, in cholangiocarcinoma expression of CEACAM6 and its clinicopathological significance have not been investigated. CEACAM6 expression status was determined and analysed with respect to various clinicopathological parameters in 23 intrahepatic cholangiocarcinomas. Additionally, we investigated effects of CEACAM6 gene in the cholangiocarcinoma cell lines. CEACAM6 gene expression in cancer tissues was higher than in noncancerous tissues in 16 of the 23 cases; however, it was not statistically significant. The tumours with elevated CEACAM6 expression showed a tendency to be associated with lymphatic invasion and stage of the disease. Interestingly, patients with high CEACAM6 expression showed a significantly poorer disease-free survival rate than those with low CEACAM6 expression. We demonstrated that CEACAM6-transfected cells were more proliferative, more invasive and more chemoresistant to gemcitabine compared to mock-transfected cells. Furthermore, CEACAM6 gene silencing by CEACAM6-specific siRNA resulted in higher chemosensitivity to gemcitabine. CEACAM6 is a potential prognostic indicator and potential chemoresistant marker to gemcitabine for patients with intrahepatic cholangiocarcinoma.